Aethlon Medical (NASDAQ:AEMD) Shares Pass Below 200 Day Moving Average – Should You Sell?

Aethlon Medical, Inc. (NASDAQ:AEMD)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.99 and traded as low as $0.59. Aethlon Medical shares last traded at $0.6005, with a volume of 44,648 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Aethlon Medical has a consensus rating of “Reduce”.

Aethlon Medical Stock Performance

The company has a 50 day moving average of $1.49 and a 200-day moving average of $1.99. The stock has a market cap of $1.42 million, a price-to-earnings ratio of -0.04 and a beta of 1.41.

Institutional Trading of Aethlon Medical

An institutional investor recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical as of its most recent filing with the Securities & Exchange Commission. 1.99% of the stock is owned by institutional investors.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.